Yang Mao-Draayer

List of Publications by Year
in descending order

56 papers	2,370 citations	257450 24 h-index	214800 47 g-index
57 all docs	57 docs citations	57 times ranked	3517 citing authors

#	Article	IF	Citations
1	Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 7-15.	3.0	40
2	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	1.9	13
3	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight, 2022, 7, .	5.0	11
4	Familial multiple sclerosis in patients with Von Hippel-Lindau disease. BMC Neurology, 2022, 22, 80.	1.8	1
5	Current and Future Biomarkers in Multiple Sclerosis. International Journal of Molecular Sciences, 2022, 23, 5877.	4.1	34
6	Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal, 2021, 27, 883-894.	3.0	27
7	A multi-center case series of sarcoid optic neuropathy. Journal of the Neurological Sciences, 2021, 420, 117282.	0.6	13
8	Toxic and Metabolic Diseases. , 2021, , 391-428.		0
9	CD6 is a target for cancer immunotherapy. JCI Insight, 2021, 6, .	5.0	18
10	20680 Characterization of Clinical and Immunological Laboratory Features in Multiple Sclerosis Patients with COVID-19. Journal of Clinical and Translational Science, 2021, 5, 144-144.	0.6	0
11	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	47
12	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. Vaccine, 2021, 39, 6111-6116.	3.8	39
13	Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis. Journal of Central Nervous System Disease, 2021, 13, 117957352110507.	1.9	6
14	Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	19
15	Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 56, 103310.	2.0	9
16	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	1.9	10
17	A prospective observational cohort study of posterior tibial nerve stimulation in patients with multiple sclerosis: design and methods. BMC Urology, 2020, 20, 58.	1.4	6
18	Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nature Communications, 2020, 11, 2856.	12.8	50

#	Article	IF	Citations
19	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nature Reviews Neurology, 2020, 16, 154-170.	10.1	65
20	Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e709.	6.0	7
21	Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis. JCI Insight, 2020, 5, .	5.0	35
22	Fundamentals of the Neurologic Exam and Other Considerations in the Setting of Progressive Neurological Disease. , 2020, , 31-38.		0
23	Bidirectional regulatory potentials of short-chain fatty acids and their G-protein-coupled receptors in autoimmune neuroinflammation. Scientific Reports, 2019, 9, 8837.	3.3	104
24	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	1.0	3
25	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	13.7	684
26	Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS. Multiple Sclerosis Journal, 2018, 24, 1795-1807.	3.0	14
27	Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1014-1022.	3.0	45
28	Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Birdâ€™s Eye View. Frontiers in Immunology, 2018, 9, 138.	4.8	41
29	Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Frontiers in Neurology, 2018, 9, 5.	2.4	153
30	S04. Multiple sclerosis and seizures: An observational study. Clinical Neurophysiology, 2018, 129, e143.	1.5	0
31	Assessment and Treatment Strategies for a Multiple Sclerosis Relapse. Journal of Immunology and Clinical Research, 2018, 5, .	0.5	5
32	The gut microbiome and microbial translocation in multiple sclerosis. Clinical Immunology, 2017, 183, 213-224.	3.2	64
33	Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients. Journal of Immunology, 2017, 198, 3069-3080.	0.8	136
34	The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clinical Immunology, 2017, 175, 10-15.	3.2	52
35	Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961773424.	0.6	8
36	Hemicholinium-3 sensitive choline transport in human T lymphocytes: Evidence for use as a proxy for brain choline transporter (CHT) capacity. Neurochemistry International, 2017, 108, 410-416.	3.8	2

#	Article	IF	Citations
37	Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmunity Highlights, 2017, 8, 12.	3.9	137
38	Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse. Frontiers in Neurology, 2017, 8, 116.	2.4	21
39	Optical coherence tomography and T cell gene expression analysis in patients with benign multiple sclerosis. Neural Regeneration Research, 2017, 12, 1352.	3.0	1
40	Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e211.	6.0	73
41	Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. International Journal of Molecular Sciences, 2015, 16, 13885-13907.	4.1	107
42	Interferon beta (IFN-Î²) treatment exerts potential neuroprotective effects through neurotrophic factors and novel neurotensin/neurotensin high affinity receptor 1 pathway. Neural Regeneration Research, 2015, 10, 1932.	3.0	6
43	Transplantation of Fas-deficient or wild-type neural stem/progenitor cells (NPCs) is equally efficient in treating experimental autoimmune encephalomyelitis (EAE). American Journal of Translational Research (discontinued), 2014, 6, 119-28.	0.0	8
44	IFN-Î² alters neurotrophic factor expression in T cells isolated from multiple sclerosis patients - implication of novel neurotensin/NTSR1 pathway in neuroprotection. American Journal of Translational Research (discontinued), 2014, 6, 312-9.	0.0	4
45	Neurosarcoidosis in a patient treated with tumor necrosis factor alpha inhibitors. Journal of Neurology, 2013, 260, 651-653.	3.6	11
46	Cross-talk between CD4+ T-cells and neural stem/progenitor cells. Journal of the Neurological Sciences, 2011, 306, 121-128.	0.6	12
47	Interferon Î²-1b directly modulates human neural stem/progenitor cell fate. Brain Research, 2011, 1413, 1-8.	2.2	18
48	Fas Receptor Modulates Lineage Commitment and Stemness of Mouse Neural Stem Cells. Neuroscience and Medicine, 2011, 02, 132-141.	0.2	3
49	Fas activation increases neural progenitor cell survival. Journal of Neuroscience Research, 2010, 88, 746-757.	2.9	35
50	Regulation of neural progenitor cell fate by anandamide. Biochemical and Biophysical Research Communications, 2010, 400, 21-26.	2.1	24
51	The effect of interferon-Î² on mouse neural progenitor cell survival and differentiation. Biochemical and Biophysical Research Communications, 2009, 388, 181-186.	2.1	29
52	Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) and Vasoactive Intestinal Peptide (VIP) Regulate Murine Neural Progenitor Cell Survival, Proliferation, and Differentiation. Journal of Molecular Neuroscience, 2008, 36, 79-88.	2.3	29
53	Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization. Multiple Sclerosis Journal, 2004, 10, 705-707.	3.0	32
54	Two Teenagers With Headaches. Pediatric Case Reviews (Print), 2003, 3, 117-126.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology, 2002, 59, 1074-1077.	1.1	45
56	Impact of Cytokines on Neural Stem/Progenitor Cell Fate. Journal of Neurology & Neurophysiology, 0, s4, .	0.1	10